Mankind Pharma announced its financial results for the first quarter of FY27, reporting a 13% year-on-year increase in revenue to ₹4,031 crores. The company also saw a significant improvement in its EBITDA, which grew to ₹1,060 crores, with the EBITDA margin expanding by 250 basis points to 26.3%. Domestic business revenue grew by 11%, driven by strong performance in chronic and BSV specialty segments.
Mankind Pharma Reports Strong Q1 FY27 Performance
Mankind Pharma Limited has announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27), showcasing robust growth across key financial metrics. The company’s total revenue from operations for the quarter stood at ₹4,031 crores, representing a significant 13% increase compared to ₹3,570 crores in Q1 FY26. This growth was primarily propelled by a strong performance in the BSV specialty business and a 29% growth in the international business.
Profitability and Margins Improve
The company demonstrated improved profitability, with EBITDA for Q1 FY27 reaching ₹1,060 crores. The EBITDA margin expanded by 250 basis points year-on-year to 26.3%, up from 23.8% in Q1 FY26. This expansion was attributed to a 230 basis point increase in gross margins and a 20 basis point benefit from operating leverage. Gross margins for the quarter were reported at 72.8%, up from 70.5% in the prior year quarter.
Key Business Segment Performance
The domestic business, excluding Consumer Healthcare, saw a revenue increase of 11% year-on-year to ₹3,180 crores. This was driven by double-digit growth in the base business and sustained momentum in chronic and BSV specialty segments. The secondary sales, as per IQVIA, grew by 12.7%, supported by healthy volume growth of 4.7%. The chronic portfolio continued its strong performance, growing by 15.8%, while the acute portfolio showed recovery, growing at 10.9%.
The Consumer Healthcare business registered a revenue of ₹246 crores in Q1 FY27. Despite softer growth, the company gained market share in key brands such as Manforce, Preganews, and Gas-o-fast. Modern trade and e-commerce share increased to 15% from 11% a year ago.
International Business Growth
The international business exhibited strong growth, with revenue increasing by 29% year-on-year to ₹605 crores. This growth was driven by a 25% increase in BSV and strong performance in the US market, supported by currency tailwinds.
Financial Highlights
Diluted Earnings Per Share (EPS) for the quarter stood at ₹13.7 per share. Cash EPS increased by 20.8% year-on-year to ₹19.2. The company also reported a reduction in its net debt to ₹3,377 crores as of June 30, 2026, with a net debt to adjusted EBITDA ratio of 0.9x. Capex spend for the quarter was ₹198 crores.
Strategic Outlook
Mankind Pharma reiterated its strategic priorities, focusing on driving scale with profitability, strengthening its presence in chronic and specialty therapies, expanding its global footprint, and accelerating innovation. The company is committed to delivering innovative, science-backed products at affordable prices and fostering a culture of collaboration and excellence.
Source: BSE
